X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

    Advanced Instruments All Set To Merge With Nova Biomedical

    Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

    Oracle Wins the Asia Pacific Biopharma Excellence Awards

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

    Advanced Instruments All Set To Merge With Nova Biomedical

    Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

    Oracle Wins the Asia Pacific Biopharma Excellence Awards

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

CARsgen Launches First-in-Class Anti-Claudin18.2 CAR-T Clinical Trial

Yuvraj_pawp by Yuvraj_pawp
11th August 2017
in Clinical Trials

CARsgen Therapeutics (CARsgen), a global leader in developing chimeric antigen receptor T-cell (CAR-T cell) therapies for solid tumors announced its first-in-class anti-Claudin18.2-CAR-T cell therapy for gastric and pancreatic cancers has entered into phase-I clinical trial and starts patients recruitment at Changhai Hospital of Shanghai, a renowned hospital of global reputation for expertise on gastroesophageal and related cancer.

Commenting on their cooperation with CARsgen on this Claudin18.2-CAR-T clinical trial, Oncologist Xianbao Zhan, Ph.D & MD, Chief of Oncology at the hospital and principal investigator on this study, said, “It is designed to develop and deliver innovative solutions and bring hope to people who are suffering from refractory and/or relapsed gastric and pancreatic cancers all over the world.”


“The Claudin18.2 program marks another major breakthrough of CARsgen following the world’s first anti-GPC3-CAR-T trial for hepatocelluar carcinoma (HCC) initiated in 2015,” said Dr.Zonghai Li, President and CEO of the company.


The company’s proprietary humanized antibody exhibited promising affinity between an antibody and an epitope, while maintaining steady specificity of which molecule reacts against certain antigenic determinants and not with others. The pre-clinical study also showed that the anti-Claudin18.2 CAR-T cell therapy combines both high safety and anti-tumor activity.


Claudin18.2 belongs to a unique family of membrane proteins that make tight junctions. Previous research has shown that its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa, but is abundant in a variety of human malignancies including gastric, pancreatic, and esophageal cancer, which qualify CLDN18.2 as a highly attractive target to develop safe and potent cancer immunotherapies.


Gastric and pancreatic cancer are among the malignancies with the highest unmet medical needs. Gastric cancer is the second leading cause of cancer deaths worldwide, and as the World Health Organization (WHO) presented in 2015, the total number of annual global gastric cancer deaths is estimated to exceed 754,000. Pancreatic cancer, with a mortality rate that closely parallels incidence, kills over 200,000 patients a year around the world, according to a Lancet report in 2016. These challenges highlight the urgent demand for novel, safe and effective therapies.


“In the future, we will continue to advance the clinical trial and facilitate its translation into robust clinical benefits,” said Li.


About CARsgen Therapeutics

CARsgen Therapeutics is a rapidly growing bio-tech start-up with the original CAR-T therapy discovery expertise, competitive GMP manufacturing capability, and global clinical development experience. CARsgen commits to delivering the most advanced yet affordable cell therapies to patients with unmet medical needs. With broad discovery pipeline across solid tumor and hematology malignancies, CARsgen proceeds the clinical development with a clear focus in CAR-T therapy for solid tumors. Several of its pioneering CAR-T cell therapies, anti-GPC3 CAR-T for hepatocellular carcinoma (HCC), anti-GPC3 CAR-T for squamous lung cancer (SLC), cancer-specific anti-EGFR CAR-T for glioblastoma multiforme (GBM) and first-in-class anti-Claudin18.2-CAR-T for gastric and pancreatic cancer, have all entered early clinical development.

For more information, please visit www.carsgen.com

Tags: Middle East & South Asia
Previous Post

First FDA-Approved Treatment for ALS in 22 Years Now Available in U.S

Next Post

A New Drug Research And Development Cooperation Reached By Chengdu Pilot And Aduro

Related Posts

Clinical Development
Articles

AI Revolutionizing Drug Discovery and Clinical Development

19th April 2025
Omics Based Clinical Trials
Asia

Asia Pacific Omics-Based Clinical Trials Market Growth

16th April 2025
Clinical Trials

Oracle Wins the Asia Pacific Biopharma Excellence Awards

21st March 2025
Clinical Trials

Bio-Rad to Acquire Stilla Technologies by Q3 2025

28th February 2025
Clinical Trials

New Endometrial Cancer Care Phase II Results Encouraging

29th August 2024
ADC Therapeutics and Freenome Enter Biomarker Development Collaboration
Clinical Trials

Duality Keeps An Eye Out For Hong Kong IPO For ADC Trials

29th August 2024
Next Post

A New Drug Research And Development Cooperation Reached By Chengdu Pilot And Aduro

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In